Study helping transgender women access HIV prevention (PrEP)
Part of Immune system & allergy, Infections clinical trials.
This study helps transgender women who are not regularly using PrEP (a daily pill to prevent HIV) get access to HIV prevention services. It uses a smartphone to take pictures and connect with support.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You were assigned male at birth and identify as a woman or transgender woman
- You are not consistently taking PrEP (fewer than 4 doses per week), or are not taking it at all
- You are not allergic to PrEP or the HIV drug tenofovir
- You speak English or Spanish (even if you cannot read or write)
- You have a smartphone that can take pictures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for cis-gender men who are HIV-negative and at risk for HIV. It tests a program to help you start and stay on PrEP (medication to prevent HIV).
This study aims to help more trans women (and other women who were assigned male at birth) use or restart PrEP, a medication that helps prevent HIV. You may be eligible if you are HIV-uninfected, live in the New Orleans area, and can do regular follow-up visits.
This study helps connect young people aged 13–24 to PrEP, a daily pill that prevents HIV. It tests whether offering PrEP in clinics or community locations makes it easier for you to get and stay on this prevention medication.
This study looks at how taking PrEP (medicine to prevent HIV) affects HIV prevention and how much it costs in real life. You may be able to join if you are HIV-negative and are interested in starting, currently using, or have used PrEP before.
This study tests a new approach to help men at risk for HIV stay healthy by providing access to PrEP through a mobile app. The goal is to see if the program helps men start and stay on PrEP compared to standard care.
This study asks people who may use PrEP—an HIV prevention medicine—about their decision to start, not start, or stop PrEP. It aims to understand needs and barriers so PrEP can work better for cisgender women and transgender people who are considering it.
Hear when a new AIDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.